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Abstract
Background: Both high concentrations of N-terminal pro-brain natriuretic peptide
(NT-proBNP) and obesity are related to higher heart failure risk. However, inverse
relationships between NT-proBNP and obesity have been reported. Therefore, it
was investigated whether the association between NT-proBNP and the risk of heart
failure differed according to obesity status.
Methods: A case-cohort study was conducted within the European Prospective
Investigation into Cancer and Nutrition (EPIC)-Potsdam, comprising a random sub-
cohort (non-cases51,150, cases513, mean age: 50.5¡9.0 years) and heart failure
cases outside the sub-cohort (n5197). Weighted Cox proportional hazards
regression was used to examine the association between NT-proBNP and heart
failure risk during a mean follow-up time of 8 years. Stratified analyses were
performed according to obesity status as defined by body mass index (,30 kg/m2
versus >30 kg/m2).
Results: Overall, NT-proBNP was associated with higher risk of heart failure after
multivariable adjustment (hazard ratio (HR) and 95% confidence interval (CI): 2.56
(1.49–4.41) for the top versus bottom tertile of NT-proBNP, ptrend:,0.01). In
stratified analyses, the shape of association was linear in non-obese and U-shaped
in obese participants: HRs (95%CI) from the first to the third tertile of NT-proBNP for
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non-obese: reference, 1.72 (0.85–3.49), 2.72 (1.42–5.22), and for obese: 3.29
(1.04–10.40), reference, 3.74 (1.52–9.21).
Conclusions: Although high circulating concentrations of NT-proBNP were
positively associated with incident heart failure in the entire sample, the association
differed according to obesity status. In obese, an increased risk of heart failure was
also observed in those with low NT-proBNP concentrations. If confirmed, this
observation warrants further investigation to understand underlying
pathophysiological mechanisms.
Introduction
Heart failure (HF) has experienced a considerable increase in prevalence and
contributes to a tremendous public health burden [1]. Despite advances in survival
and therapeutic opportunities, HF prognosis remains poor, characterized by high
fatality and hospitalization rates [1, 2]. The need for action in the context of
preventive measures and improvements in risk prediction is obviously desirable.
Brain natriuretic peptides (BNP) and N-terminal pro brain natriuretic peptides
(NT-proBNP) are of promising value in early disease prevention and have
received increasing interest as cardiac markers [3]. Both are produced in
equimolar amounts by enzymatic cleavage of the precursor hormone pro-brain
natriuretic peptide (proBNP). ProBNP in turn is mainly released from ventricular
myocytes upon activation of the BNP gene, which is induced by excessive
stretching of the ventricles due to volume overload and increased filling pressure
[4]. While physiological effects of NT-proBNP are currently unknown, BNP
affects the vasculature by vasodilation, increased diuresis/natriuresis, and
inhibiting renin and aldosterone production as well as vascular and cardiac
myocyte growth [4]. Because of the high sensitivity and specificity [5] regarding
HF diagnosis, severity assessment, prognosis and therapy [3], the European
Society of Cardiology (ESC) has incorporated the measurement of BNP and NT-
proBNP into their Guidelines for the diagnosis and treatment of acute and chronic
heart failure [6] in 2008.
Besides having diagnostic properties, natriuretic peptides might be of
considerable predictive value, as increasing evidence indicated strong positive
associations between BNP and NT-proBNP levels and the risk of different
cardiovascular endpoints [7]. Recently, prospective studies have consistently
shown positive associations between BNP/NT-proBNP concentrations and the
risk of incident HF [8–11].
Overweight and obesity are strong risk factors for HF [12]. The use of highly
sensitive and easily measurable biomarkers would be of great benefit for HF
prevention, especially in obese, since sensitivity and specificity of traditional
devices (e.g. echocardiogram) might be limited in these individuals [13].
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Interestingly, better outcomes in morbidity and mortality have been reported
among HF patients with overweight and obesity when compared to HF patients
with normal weight - a phenomenon termed as ‘‘obesity paradox’’ [14]. Similarly,
contradictions emerged with BNP related peptides: despite increased risk of HF
with both high concentrations of BNP/NT-proBNP and with the presence of
obesity, cross-sectional studies reported inverse associations between natriuretic
peptides and markers of anthropometry in individuals with and without HF
compared to those with normal weight [15–18]. A ‘‘natriuretic peptides
deficiency’’ in obese has been speculated [18]. Hence, the diagnostic/prognostic
usefulness of BNP/NT-proBNP has been questioned and body mass indices
(BMI)-specific threshold values of natriuretic peptides have been recommended
to improve diagnostic sensitivity [15, 16].
As far as known, there are no studies that prospectively investigated whether the
relationship between NT-proBNP and HF risk differs between obese and non-
obese persons. Therefore, the aim of this study was to examine the longitudinal
association between NT-proBNP and HF risk with a special emphasis on obesity.
Overall, a positive association was hypothesized, which was expected to be weaker
in obese compared to non-obese individuals.
Materials and Methods
Ethics statement
The present investigation conforms to the principles outlined in the Declaration
of Helsinki. All participants gave their written informed consent, and the Ethics
Committee of the Federal State Brandenburg approved all study procedures.
Study population and design
The European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam
comprises 27,548 participants (16,644 women and 10,904 men) aged 35–65 years
in women and 40–65 years in men. The recruitment procedures between 1994 and
1998 included physical examinations (e.g. anthropometric measures and blood
drawing), a personal interview and questionnaires on socio-demographic and
lifestyle characteristics as well as prevalent diseases [19]. Every two to three years,
participants were re-contacted and interviewed by questionnaires about lifestyle
and newly diagnosed diseases [20]. In the present analysis, the first four follow-up
waves were considered, corresponding to a time frame from August 1994 to
December 2008. Response rates so far exceeded 90% at each occasion.
A case-cohort study design was used to investigate the relationship between
NT-proBNP and HF risk [21]. With this type of study design, results are expected
to be generalizable without the need to measure biomarker levels in the entire
cohort. Accordingly, a random sample of 1,294 participants was drawn and added
up with all incident HF cases. Some exclusion was required for the current
analyses (Figure S1). This involved 29 participants with either a prevalent/not
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verifiable HF at baseline or without any follow-up information. Further exclusion
criteria were missing/inappropriate blood samples (n5196) and missing
information about covariates (n520), leading to a final study population of 1,360
participants (sub-cohort: n51,163 (including 13 HF cases), HF cases outside the
sub-cohort: n5197).
Outcome Ascertainment
In the present analyses only medically confirmed HF cases were used. Those were
identified by several sources of information: self-report [21], death certificates
(diagnosis I50 of International Classification of Diseases, 10th revision (ICD-10)
as underlying cause of death), and a link to the hospital information system of the
major hospital in the Potsdam area. Additionally, participants with incident
myocardial infarction or reported drug use typical for HF treatment have been
actively enquired for HF. Attending physicians confirmed the diagnosis with
specific validation forms and gave information about performed diagnostic
procedures. All confirmed cases then were classified into definite, probable and
possible HF according to ESC-Guidelines [22]. If the two required criteria
(presence of typical symptoms and objective evidence of cardiac dysfunction by
echocardiography) were fulfilled, they were classified as definite. Cases were
adjudicated as probable, either if they were not symptomatic but had pathological
evidence from echocardiogram, or if they were symptomatic but confirmed by
other objective evidence (cardiac catheter, electrocardiogram, chest x-ray). Cases
with less provided information were defined as possible and if there was no
information at all they were excluded from analysis (n51).
Assessment of Exposure and Covariates
NT-proBNP was measured in 2012 at the Institute of Clinical Chemistry,
University of Magdeburg, using a solid-phase, two-site chemiluminescent
immunometric assay (IMMULITE 2000 Systems Analyzers, SIEMENS). The mean
with-in run coefficient of variation was 5.4% at a concentration of 35.6 pg/ml and
4.1% at 29,7 pg/ml. The overall variation coefficients throughout the analyses
were 6.4% and 4.7% at the same sample concentration. The analytic measurement
range for NT-proBNP was 20.0–35,000 pg/ml. Concentrations below the lower
limit of detection (20 pg/ml) (n5185, o14.8%) were set to 10 pg/ml.
Several other biomarkers (e.g. total cholesterol, high density lipoprotein (HDL)
cholesterol, high sensitivity C-reactive protein (hsCRP) and creatinine) had been
analysed at the Department of Internal Medicine, University of Tu¨bingen [23] and
at the Stichting Huisartsen Laboratorium (Breda, The Netherlands).
At baseline, participants’ weight and height were measured without wearing
shoes with a precision of 0.1 kg and 0.1 cm, respectively. BMI was calculated by
dividing body weight by body height squared (kg/m2) to assess general obesity
(BMI>30 kg/m2). Waist circumference (WC) was measured at the midway
between the lower ribs and the iliac crest and hip circumference over the buttocks.
NT-ProBNP, Obesity and Heart Failure Risk
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Abdominal obesity was defined in two ways, using WC (men: >102 cm, women:
>88 cm) and waist to hip ratio (WHR) (men:.1, women.0.85) [24].
Prevalent hypertension was defined as systolic blood pressure >140 mmHg or
diastolic blood pressure >90 mmHg or self-reporting of a diagnosis or use of
antihypertensive medication. Participants were classified as having prevalent
coronary heart disease (CHD), if they had either myocardial infarction or angina
pectoris prior to recruitment. The prevalence of diabetes at baseline was assessed
by using information on self-reported medical diagnosis, medication records and
dieting behaviour. Physical activity was defined as the mean time spent on leisure
time physical activities (hours/week) during summer and winter. Dietary habits,
including alcohol consumption during the preceding year, were assessed by a
validated self-administered food frequency questionnaire. All interviews and
physical examinations were standardized and conducted by trained personnel
[19].
Statistical Analysis
Men had lower NT-proBNP levels than women; therefore, sex-specific tertiles
were generated. Age- and sex-adjusted baseline characteristics were compared
across NT-proBNP tertiles within the sub-cohort and between cases and the sub-
cohort using analysis of covariance.
The association between NT-proBNP and the risk of HF was investigated by
calculating hazard ratios (HR) and 95% confidence intervals (CI) across NT-
proBNP tertiles using Cox proportional hazards regression modified by Prentice
[25]. Age was used as the underlying time variable in the counting process with
entry time defined as the participants’ age at recruitment and exit time as age at
time of HF diagnosis or censoring.
The baseline hazard function was allowed to vary by age (one-year integer).
Three adjustment models were used to take into account a priori selected
potential confounders: sex-adjusted (Model 1), additionally adjusted for
educational degree (no vocational training/vocational training (reference);
technical college; university), physical activity (hours/week), smoking status
(never smoker (reference); former smoker; smoker ,20cigarettes/day, smoker
>20cigarettes/day), alcohol consumption (men: 0 g/day; .0–#12 g/day (refer-
ence); .12–#24 g/day; .24 g/day; women: 0 g/day; .0–#6 g/day (reference);
.6–#12 g/day; .12 g/day), BMI and WC (continuously (if applicable)),
prevalent diseases (diabetes, CHD, hypertension (present/absent)) (Model 2), and
further adjusted for hsCRP, creatinine, total and HDL cholesterol (quartiles)
(Model 3).
The shape of the associations between NT-proBNP and HF risk was determined
using restricted cubic spline Cox regression analysis (Model 3) adapted to the
case-cohort design with four knots at fixed values: 22.2, 30, 100, and 300 pg/ml.
These reflected about the 15th, 25th, 75th and 95th percentiles of the NT-proBNP
distribution in the entire case-cohort and guaranteed sufficient proportions of
participants in all sections (including marginal). Furthermore, these values
NT-ProBNP, Obesity and Heart Failure Risk
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ensured that the number of participants did not differ greatly between knots. The
respective median NT-proBNP value of 55 pg/ml was used as reference. Cox
proportional hazards regression analysis per continuous increase of NT-proBNP
was performed to demonstrate a linear association curve in direct comparison to
the restricted cubic splines.
All analyses were performed overall and stratified for general obesity (BMI,/
>30 kg/m2). Several sensitivity analyses were carried out, including the exclusion
of non-‘‘definite’’ HF cases and diabetics, and further adjustment for glucose and
HbA1c. Additionally, stratified analyses were repeated interchanging BMI with
parameters of abdominal obesity (WC and WHR).
The validity of the proportional hazards assumption was explored within the
sub-cohort by calculating Schoenfeld residuals [26] for NT-proBNP and plotting
them against time. No violation was observed. All statistical analyses were
performed using SAS software package, release 9.2 (SAS Institute, Cary, NC) and
p,0.05 was used to indicate statistical significance.
Results
Analyses were based on a case-cohort comprising 1,150 non-cases and 210 cases of
HF that occurred during a mean follow-up period of 8.3¡1.5 years. The mean age
of the sub-cohort was 50.5 years (standard deviation: 9.0 years). Medians and
interquartile ranges of NT-proBNP (in pg/ml) were 35.4 [11–67.2] in men and
60.1 [39.2–97.0] in women of the sub-cohort and 84.8 [41.6–206.3] in male and
104.2 [54.7–203.5] in female HF cases. Table 1 depicts age- and sex-adjusted
baseline characteristics of the study participants across NT-proBNP tertiles within
the sub-cohort and compared between HF cases and the sub-cohort. The
participants’ age was higher with each higher tertile of NT-proBNP, whereas
anthropometric parameters (BMI, WC and WHR) were lowest in the higher
tertiles. BMI was inversely associated to NT-proBNP across tertiles (p50.02).
Also, on a continuous scale a very weak negative correlation between BMI and
NT-proBNP was observed in the sub-cohort (Spearman partial correlation
coefficients adjusted for age and sex520.10). Comparing sub-cohort and HF
cases, the latter were clearly older, more likely to be male and had higher average
NT-proBNP concentrations. Furthermore, all anthropometric measures were
higher in cases than in persons belonging to the sub-cohort.
Among participants of the sub-cohort, 16.8% were general obese (BMI>30
kg/m2). Baseline characteristics according to tertiles of NT-proBNP in obese
(n5195) and non-obese (n5968) sub-cohort members are presented in Table 2.
As expected, obese participants had much higher proportions of prevalent diseases
compared to those who were not obese. As seen from Table 2, in particular the
proportion of diabetics was about 3 times higher in obese than in non-obese
participants, which equals a proportion of 10.9% obese diabetics in the first tertile
of NT-proBNP.
NT-ProBNP, Obesity and Heart Failure Risk
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Table 1. Age- and sex-adjusted baseline characteristics of the sub-cohort and the heart failure cases in EPIC-Potsdam.
Sub-cohorta (n51,163)
Tertiles of NT-proBNPb
Characteristics 1st 2nd 3rd Sub-cohorta HF Casesc
(n5385) (n5390) (n5388) (n51,163) (n5197)
NT-proBNPd, pg/ml
Men 25 (26) 36 (24) 184 (25) 91 (15) 190 (29)
Women 31 (4) 63 (4) 148 (4) 82 (5) 222 (17)
Socio-demographics
Agee, years 47.4 (8.3) 50.2 (9.1) 53.8 (8.5) 50.5 (9.0) 59.0 (6.4)
Womene, % 61.6 60.8 60.8 61.0 35.0
Educational degree, %
(No) vocational training 38.8 38.4 37.2 38.3 41.4
Technical college 24.6 20.4 21.9 22.6 26.3
University 36.6 41.2 40.9 39.1 32.2
Anthropometry
BMId, kg/m2 26.6 (0.2) 26.1 (0.2) 25.8 (0.2) 26.3 (0.1) 28.0 (0.3)
Men 27.2 (0.3) 27.1 (0.3) 26.6 (0.3) 27.0 (0.2) 28.4 (0.3)
Women 26.1 (0.3) 25.4 (0.3) 25.2 (0.3) 25.7 (0.2) 28.3 (0.3)
Waist circumferenced, cm
Men 94.6 (0.8) 95.0 (0.8) 93.8 (0.8) 94.9 (0.5) 99.0 (0.9)
Women 81.8 (0.7) 79.8 (0.7) 79.8 (0.7) 80.9 (0.4) 86.4 (1.4)
Waist to hip ratiod
Men 0.94 (0.01) 0.95 (0.00) 0.94 (0.01) 0.95 (0.00) 0.97 (0.01)
Women 0.80 (0.00) 0.79 (0.00) 0.79 (0.00) 0.80 (0.00) 0.81 (0.01)
Lifestyle
Physical activity, h/wk 0.92 (0.09) 1.10 (0.09) 0.99 (0.09) 0.98 (0.05) 0.79 (0.12)
Alcoholic intake, g/d 15.5 (0.8) 15.6 (0.8) 15.8 (0.8) 15.6 (0.5) 13.8 (1.2)
Smoking, %
Never 44.8 41.3 44.3 44.0 36.3
Former 34.6 36.9 35.7 35.6 34.9
,20 cigarettes/day 15.7 16.2 13.5 14.8 17.1
>20 cigarettes/day 4.9 5.6 6.5 5.6 11.7
Medical history, %
Diabetes mellitus 5.5 2.1 4.6 4.6 19.3
Hypertension 49.1 46.9 58.3 53.0 64.7
Hyperlipidemiaf 29.9 27.7 30.4 30.7 42.6
Coronary heart disease 5.2 6.0 13.9 9.3 24.7
Biomarkers, mg/dl
hsCRP 0.21 (0.02) 0.19 (0.02) 0.28 (0.02) 0.23 (0.01) 0.32 (0.03)
Creatinine 0.82 (0.01) 0.81 (0.01) 0.83 (0.01) 0.82 (0.01) 0.88 (0.02)
Total cholesterol 203 (1.8) 197 (1.8) 193 (1.8) 199 (1.1) 202 (2.7)
NT-ProBNP, Obesity and Heart Failure Risk
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In Table 3 HRs of HF according to tertiles of NT-proBNP are shown overall
and stratified for obesity status. Overall, persons within the third tertile of NT-
proBNP had a 2- to 3-times higher risk of HF compared to participants from the
first tertile. This result was irrespective of the analytic model applied. In stratified
analyses, however, a clear linear trend was identified among non-obese
participants while a U-shape was recognizable in obese individuals. These findings
were again independent of the different multivariable adjustments applied in the
three analytic models. In contrast, using the first tertile as reference category in
obese, the respective HRs (95%CI) were: 0.30 (0.10–2.96) for the second and 1.14
(0.41–3.17) for the third tertile after multivariable adjustment.
Results from the restricted cubic spline Cox regression supported these findings
(Figure 1). HRs are plotted comparing a linear (dashed line) and a non-linear
(solid line) relationship between NT-proBNP and the risk of HF for non-obese
and obese participants. In non-obese, the association was approximately linear,
while in obese the non-linear model fitted the data better than the linear model.
Actually, in the linear model no effect was visible, as the risk-increase with both
very low and very high values of NT-proBNP and the low risk with intermediate
NT-proBNP values canceled each other out.
The relationship between NT-proBNP and HF risk was also modified by
abdominal obesity as defined by WC or WHR (Tables S1, S2, S3, S4). While
results from analyses on WC (Table S3) were comparable to those of BMI, the U-
shaped association between NT-proBNP and HF risk was less pronounced in
obese defined by WHR. In particular, the higher HF risk originally seen in those
with low NT-proBNP levels became weaker (Table S4).
Among obese participants, both the exclusion of diabetics (n544) and of non-
definite HF cases (n520) even strengthened the U-shaped association, although
lowering the precision of the estimate (HRs (95% CI) for obese participants after
exclusion of diabetics: tertile 1: 6.81 (2.21–21.03), tertile 2: reference, tertile 3: 7.28
(2.69–19.68), and after exclusion of non-definite cases: tertile 1: 3.42 (0.85–13.84),




Characteristics 1st 2nd 3rd Sub-cohorta HF Casesc
(n5385) (n5390) (n5388) (n51,163) (n5197)
HDL cholesterol 48.5 (0.7) 50.0 (0.7) 50.7 (0.7) 49.6 (0.4) 46.7 (0.1)
Baseline characteristics are expresses as age- and sex-adjusted means (standard error) or percentages.
a the sub-cohort included 13 heart failure cases.
b tertiles of N-terminal pro brain natriuretic peptide (NT-proBNP) have been generated sex-specifically.
c included only participants, who became cases after baseline and where not in the sub-cohort.
d expressed as age-adjusted means (standard error).
e expressed as unadjusted means (standard deviation) or percentages.
f prevalent hyperlipidemia was defined by self-reporting of a confirmed diagnosis and/or the use of antihyperlipidemic drugs.
doi:10.1371/journal.pone.0113710.t001
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glucose and HbA1c did not substantially alter the risk estimates in both obese and
non-obese.
Discussion
In this prospective study, NT-proBNP was positively associated with the risk of
HF. However, in stratified analyses differences were observed between non-obese
and obese participants. In the non-obese, the HF risk rose monotonously with
Table 2. Age- and sex-adjusted baseline characteristics of the sub-cohort (n51,163) according to tertiles of NT-proBNP, stratified by status of obesity.
Tertiles of NT-proBNPa
Characteristics 1st 2nd 3rd
Non-obese (BMI,30) (n5324) (n5322) (n5322)
NT-proBNPb, pg/ml 26.0 (5.1) 53.3 (5.0) 154.3 (5.1)
BMI, kg/m2 25.2 (0.1) 24.7 (0.1) 24.7 (0.1)
Agec, years 47.1 (8.1) 49.0 (8.9) 53.3 (8.5)
Womenc, % 60.8 62.7 60.9
Physical activity, h/wk 0.88 (0.1) 1.16 (0.1) 1.02 (0.1)
Alcoholic intake, g/d 16.2 (0.8) 15.7 (0.8) 15.9 (0.9)
Current smoking, % 20.1 21.7 21.4
University degree, % 38.5 44.5 42.7
Medical history, %
Diabetes mellitus 4.5 1.2 3.5
Hypertension 43.8 40.1 54.2
Hyperlipidemiad 27.7 24.7 26.3
Coronary heart disease 5.2 4.7 13.1
Obese (BMI>30) (n561) (n568) (n566)
NT-proBNPb, pg/ml 34.4 (57.7) 44.8 (52.7) 210.3 (53.6)
BMI, kg/m2 33.1 (0.4) 33.2 (0.4) 32.7 (0.4)
Agec, years 49.2 (9.3) 55.8 (7.8) 56.2 (7.9)
Womenc, % 65.6 51.5 60.6
Physical activity, h/wk 1.20 (0.2) 0.78 (0.2) 0.81 (0.2)
Alcoholic intake, g/d 11.8 (2.0) 15.0 (1.9) 15.4 (1.9)
Current smoking, % 23.5 21.9 13.1
University degree, % 28.9 24.7 29.7
Medical history, %
Diabetes mellitus 10.9 5.8 11.3
Hypertension 71.0 81.6 81.9
Hyperlipidemiad 38.4 43.3 51.6
Coronary heart disease 4.8 12.4 17.8
Baseline characteristics are expresses as age- and sex-adjusted means (standard error) or percentages.
a tertiles of N-terminal pro brain natriuretic peptide (NT-proBNP) have been generated sex-specifically.
b expressed as age-adjusted means (standard error).
c expressed as unadjusted means (standard deviation) or percentages.
d prevalent hyperlipidemia was defined by self-reporting of a confirmed diagnosis and/or the use of antihyperlipidemic drugs.
doi:10.1371/journal.pone.0113710.t002
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higher NT-proBNP concentration. In contrast, a U-shaped relationship between
NT-proBNP and HF risk was observed in obese. Taking into account the shape of
the relationship, it could be demonstrated that those with both low and high NT-
proBNP concentrations were at higher risk of HF.
Evidence on the association between NT-proBNP and the future HF risk is
limited to four cohort studies: the Malmo¨ Diet and Cancer Study [8], the
Rotterdam Study [9], the Rochester Epidemiology Project [10] and the
Cardiovascular Health Study [11], which were conducted mainly in elderly adults.
These studies consistently reported positive associations between NT-proBNP and
HF risk and therefore confirm the overall, non-stratified result of the present
analysis. However, this study went further and it presents for the first time
analyses that examined the impact of obesity on the association between NT-
proBNP and HF risk in a prospective manner. The influence of obesity on NT-
Table 3. Association between NT-proBNP and the risk of incident heart failure, overall and stratified by status of obesity.
Tertiles of NT-proBNP
1st 2nd 3rd
Non-cases/cases n 385/27 386/44 379/139
Person-yearsa 3,221 3,233 3,146
HR HR (95% CI) HR (95% CI) p*
Model 1b Reference 1.12 (0.65–1.92) 2.57 (1.59–4.17) ,0.01
Model 2c# Reference 1.11 (0.62–2.00) 2.49 (1.48–4.21) ,0.01
Model 3d# Reference 1.17 (0.64–2.12) 2.56 (1.49–4.41) ,0.01
Non-obese (BMI,30)
Non-cases/cases n 324/15 321/29 316/90
Person-yearsa 2,720 2,684 2,641
HR HR (95% CI) HR (95% CI) p*
Model 1b Reference 1.48 (0.74–2.95) 2.99 (1.61–5.54) ,0.01
Model 2c Reference 1.56 (0.79–3.07) 2.64 (1.40–4.98) ,0.01
Model 3d Reference 1.72 (0.85–3.49) 2.72 (1.42–5.22) ,0.01
Obese (BMI>30)
Non-cases/cases n 61/12 65/15 63/49
Person-yearsa 501 549 504
HR HR (95% CI) HR (95% CI) p$
Model 1b 1.92 (0.71–5.18) Reference 3.30 (1.59–6.84) ,0.01
Model 2c 3.58 (1.13–11.35) Reference 3.95 (1.69–9.23) ,0.01
Model 3d 3.29 (1.04–10.40) Reference 3.74 (1.52–9.21) ,0.01
a Person years are calculated from the sub-cohort (n51,163) only.
b adjusted for sex, stratified for baseline age.
c Model 1 further adjusted for educational degree, physical activity, smoking status, alcohol consumption, waist circumference, and prevalent diseases
(diabetes, coronary heart disease, hypertension).
d Model 2 further adjusted for biomarkers (hsCRP, creatinine, total cholesterol and HDL cholesterol).
*p for trend across tertiles was calculated by using tertiles of N-terminal pro brain natriuretic peptide (NT-proBNP) as a categorical variable in the respective
Cox proportional hazards regression models.
$the p value for nonlinearity was calculated by Wald chisquare test following restricted cubic spline Cox regression analysis.
#in the non-stratified models, body mass index (BMI) was also included in the adjustment set.
doi:10.1371/journal.pone.0113710.t003
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proBNP has to a great extend been investigated by cross-sectional studies, e.g.
Rivera et al. and Cheng et al. [17, 18], but did not include the relation to HF
incidence. However, some clinical longitudinal studies [15, 16, 27–29] have
investigated the risk of mortality according to NT-proBNP concentrations in
different weight classes. Those reported inconsistent results but largely confirmed
the suitability of NT-proBNP as prognostic marker for mortality in both obese
and non-obese cardiac patients. However, Christensen et al. [15] proposed the use
of BMI-specific NT-proBNP cut-points to optimize sensitivity in obese
individuals with possible decompensated HF.
Figure 1. Hazard ratio curves for the association between NT-proBNP levels and the risk of heart
failure in non-obese (n51,095) and obese (n5265) participants. Results are illustrated for non-obese
(BMI,30 kg/m2) and obese (BMI>30 kg/m2) participants. The solid lines indicate hazard ratios of heart failure
as obtained by restricted cubic spline Cox regression with knots (marked by vertical dotted lines) placed at
fixed values (,15th, 25th, 75th and 95th percentile of the distribution of NT-proBNP in the entire case-cohort).
The reference was set at ,50th percentile555 pg/ml of NT-proBNP. The dashed lines indicate hazard ratios
of heart failure as observed by Cox regression analysis per continuous increment of NT-proBNP. Hazard
ratios curves are adjusted for age, sex, educational degree, physical activity, smoking status, alcohol
consumption, WC, prevalent diseases (diabetes, CHD, hypertension) and biomarkers (hsCRP, creatinine,
total cholesterol and HDL cholesterol).
doi:10.1371/journal.pone.0113710.g001
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Different pathophysiological mechanisms might be responsible for a higher risk
of HF with low NT-proBNP in obese individuals. First, BNP secretion may be
reduced in some obese with high risk of HF. One biologically plausible
explanation is the O-glycolysation of proBNP. If proBNP is present in
glycosylated form, especially near the cleavage site, it cannot be further converted
into BNP and NT-proBNP [30]. This glycosylation process might be promoted by
elevated blood glucose levels and indicate an initial or advanced state of insulin
resistance. Indeed, insulin has also been linked to natriuretic peptides [31, 32]. In
particular, Khan and colleagues [31] observed markedly lower NT-proBNP levels
in both obese and non-obese, insulin resistant participants compared to non-
obese, insulin sensitive ones. When comparing non-obese with obese insulin
sensitive participants, differences in NT-proBNP levels were negligible. This might
also explain the higher proportion of prevalent diabetics among non-obese
participants with low NT-proBNP levels observed in the present study. Second,
composition and type of adipose tissue could have an influence on the
degradation of NT-proBNP. Pivovarova et al. [32] studied the gene expression of
natriuretic peptide clearance receptors in visceral and subcutaneous adipose tissue
depots and the acute effect of insulin infusion. They observed higher gene
expression in visceral adipose tissue compared to subcutaneous adipose tissue,
and the latter being up-regulated by insulin. Indeed, both subcutaneous and
visceral adipose tissues have been associated with lower NT-proBNP [18],
suggesting a more favorable adipose tissue distribution with higher NT-proBNP
levels. Interestingly, analyses with parameters of abdominal obesity differed only
with regard to WHR, where the U-shape was less pronounced in obese. In fact,
WHR has been considered advantageous over BMI for predicting CVD and the
metabolic syndrome [33, 34]. WHR might contain information that improves
discrimination between obese and non-obese participants.
Some limitations merit consideration: First, the study was limited by the
relatively small number of obese participants and thereby the low number of cases
in the stratified analysis. Therefore, the risk of chance findings was increased, and
the authors refrained from several more detailed analyses. Second, the risk of
residual and unmeasured confounding cannot be ruled out. The potential of
confounding may be higher in obese compared to non-obese, demonstrated by
greater differences in baseline characteristics and hence in risk estimates before
and after multivariable adjustment. Despite a very comprehensive consideration
of possible confounders, factors such as insulin resistance could not be accounted
for in the present investigation. However, in addition to the adjustment for
diabetes, further adjustment for glucose and HbA1c did not change the U-shaped
association observed in obese participants and, on the contrary, the exclusion of
diabetics even strengthened this finding. Nevertheless, there might be a
considerable difference between impaired fasting glucose and impaired glucose
tolerance in the onset of heart failure, which could not be accounted for [35].
Strengths of the present study include its prospective design and the wide range
of considered covariates and exposure variables, including measures of general
and abdominal obesity. Furthermore, analyses were performed using NT-proBNP
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rather than BNP, which might be of beneficial value: NT-proBNP is a biologically
inert molecule, reported to be very stable, assuming a lower amount of
degradation after years of storage. Lastly, case assessment was carried out carefully
and it was distinguished between definite, probable and possible cases according
to the ESC criteria. Excluding probable and possible cases from the analysis even
strengthened the observed associations.
Conclusions
The findings of the present analyses demonstrate that, regardless of obesity status,
high circulating concentrations of NT-proBNP were positively associated to
incident HF. These findings are of great importance as they confirm the clinical
feasibility of NT-proBNP in obese individuals, who still represent a crucial risk
group, where sensitivity and specificity of traditional devices might be limited
[13]. However, the present analysis suggests that people with obesity and low
plasma NT-proBNP are also at higher risk of HF. Further studies to support these
findings are needed.
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Figure S1. Flow chart of the number and reasons of excluded participants in
the case-cohort design. * including 13 cases of heart failure (HF)
doi:10.1371/journal.pone.0113710.s001 (TIF)
Table S1. Age- and sex-adjusted baseline characteristics of the sub-cohort
(n51,163), according to tertiles of NT-proBNP, stratified by status of obesity
defined by waist circumference (WC).
doi:10.1371/journal.pone.0113710.s002 (DOC)
Table S2. Age- and sex-adjusted baseline characteristics of the sub-cohort
(n51,163), according to tertiles of NT-proBNP, stratified by status of obesity
defined by waist to hip ratio (WHR).
doi:10.1371/journal.pone.0113710.s003 (DOC)
Table S3. Association between NT-proBNP and the risk of incident heart
failure, stratified by status of obesity defined by waist circumference (WC).
doi:10.1371/journal.pone.0113710.s004 (DOC)
Table S4. Association between NT-proBNP and the risk of incident heart
failure, stratified by status of obesity defined by waist to hip ratio (WHR).
doi:10.1371/journal.pone.0113710.s005 (DOC)
Acknowledgments
The authors would like to thank all study participants for their cooperation,
Wolfgang Fleischhauer for case ascertainment, Ellen Kohlsdorf for data
management, and Wolfgang Bernigau for statistical and graphical support.
NT-ProBNP, Obesity and Heart Failure Risk
PLOS ONE | DOI:10.1371/journal.pone.0113710 November 25, 2014 13 / 16
Author Contributions
Conceived and designed the experiments: CW HB. Performed the experiments:
JW RdG. Analyzed the data: JW RdG. Contributed reagents/materials/analysis
tools: AF HWH SW BI HB CW. Wrote the paper: JW. Supervision of the project:
BB CW. Interpretation and critical revision of the manuscript: JW BB RdG AF
HWH SW BI HB CW.
References
1. Kannel WB (2000) Incidence and epidemiology of heart failure. Heart Fail Rev 5:167–173.
2. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, et al. (2012) ESC guidelines for the
diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and
Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in
collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803–869.
3. Daniels LB, Maisel AS (2007) Natriuretic peptides. JACC 50:2357–2368.
4. Hall C (2004) Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 6:257–260.
5. Choi HS, Kim KH, Yoon HJ, Hong YJ, Kim JH, et al. (2012) Usefulness of cardiac biomarkers in the
prediction of right ventricular dysfunction before echocardiography in acute pulmonary embolism.
J Cardiol 60:508–513.
6. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. (2008) ESC Guidelines
for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis
and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology.
Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the
European Society of Intensive Care Medicine (ESICM). Eur Heart J 29:2388–2442.
7. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, et al. (2009) B-type natriuretic
peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies.
Circulation 120:2177–2187.
8. Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, et al. (2010) Assessment of
conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart
failure and atrial fibrillation. JACC 56:1712–1719.
9. Rutten JH, Mattace-Raso FU, Steyerberg EW, Lindemans J, Hofman A, et al. (2010) Amino-terminal
pro-B-type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the
population: the Rotterdam study. Hypertension 55:785–791.
10. McKie PM, Cataliotti A, Lahr BD, Martin FL, Redfield MM, et al. (2010) The prognostic value of N-
terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage
A/B heart failure subjects. JACC 55:2140–2147.
11. Kalogeropoulos AP, Georgiopoulou VV, deFilippi CR, Gottdiener JS, Butler J (2012)
Echocardiography, natriuretic peptides, and risk for incident heart failure in older adults: the
Cardiovascular Health Study. JACC Cardiovascular imaging 5:131–140.
12. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, et al. (2002) Obesity and the risk of heart
failure. N Engl J Med 347:305–313.
13. Baessler A, Strack C, Rousseva E, Wagner F, Bruxmeier J, et al. (2012) Growth-differentiation factor-
15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid
obesity. Eur J Heart Fail 14:1240–1248.
14. Habbu A, Lakkis NM, Dokainish H (2006) The obesity paradox: fact or fiction? Am J Cardiol 98:944–
948.
15. Christenson RH, Azzazy HM, Duh SH, Maynard S, Seliger SL, et al. (2010) Impact of increased body
mass index on accuracy of B-type natriuretic peptide (BNP) and N-terminal proBNP for diagnosis of
decompensated heart failure and prediction of all-cause mortality. Clin Chem 56:633–641.
NT-ProBNP, Obesity and Heart Failure Risk
PLOS ONE | DOI:10.1371/journal.pone.0113710 November 25, 2014 14 / 16
16. Lorgis L, Cottin Y, Danchin N, Mock L, Sicard P, et al. (2011) Impact of obesity on the prognostic value
of the N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with acute myocardial infarction.
Heart 97:551–556.
17. Rivera M, Cortes R, Salvador A, Bertomeu V, de Burgos FG, et al. (2005) Obese subjects with heart
failure have lower N-terminal pro-brain natriuretic peptide plasma levels irrespective of aetiology.
Eur J Heart Fail 7:1168–1170.
18. Cheng S, Fox CS, Larson MG, Massaro JM, McCabe EL, et al. (2011) Relation of visceral adiposity to
circulating natriuretic peptides in ambulatory individuals. Am J Cardiol 108:979–984.
19. Boeing H, Wahrendorf J, Becker N (1999) EPIC-Germany–A source for studies into diet and risk of
chronic diseases. European Investigation into Cancer and Nutrition. Ann Nutr Metab 43:195–204.
20. Bergmann MM, Bussas U, Boeing H (1999) Follow-up procedures in EPIC-Germany–data quality
aspects. European Prospective Investigation into Cancer and Nutrition. Ann Nutr Metab 43:225–234.
21. di Giuseppe R, Buijsse B, Hirche F, Wirth J, Arregui M, et al. (2013) Plasma Fibroblast Growth Factor
23, Parathyroid Hormone, 25-HydroxyvitaminD3 and risk of Heart Failure: a prospective, case-cohort
study. J Clin Endocrinol Metab 99:947–55.
22. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, et al. (2005) [Guidelines for the Diagnosis and
Treatment of Chronic Heart Failure: executive summary (update 2005)]. Rev Esp Cardiol 58:1062–1092.
23. di Giuseppe R, Pechlivanis S, Fisher E, Arregui M, Weikert B, et al. (2013) Microsomal triglyceride
transfer protein 2164 T.C gene polymorphism and risk of cardiovascular disease: results from the
EPIC-Potsdam case-cohort study. BMC Med Genet 14:19.
24. Haftenberger M, Lahmann PH, Panico S, Gonzalez CA, Seidell JC, et al. (2002) Overweight, obesity
and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into
Cancer and Nutrition (EPIC). Public Health Nutr 5:1147–1162.
25. Prentice R (1986) A case-cohort design for epidemiologic cohort studies and disease prevention trials.
Biometrika 73:1–11.
26. Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika
69:239–241.
27. Choi SG, Jeong MH, Ahn Y, Cho JG, Kang JC, et al. (2010) Relationship between obesity and N-
terminal brain natriuretic Peptide level as a prognostic value after acute myocardial infarction. Korean
Circ J 40:558–564.
28. Frankenstein L, Remppis A, Nelles M, Schaelling B, Schellberg D, et al. (2008) Relation of N-
terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to
obesity status. Eur Heart J 29:2634–2640.
29. Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RR, Lainchbury JG, Richards AM, et al. (2007)
Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain
natriuretic peptide in patients with acute dyspnea. Arch Intern Med 167:400–407.
30. Semenov AG, Postnikov AB, Tamm NN, Seferian KR, Karpova NS, et al. (2009) Processing of pro-
brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin
Chem 55:489–498.
31. Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, et al. (2011) Cardiac natriuretic
peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol
Metab 96:3242–3249.
32. Pivovarova O, Gogebakan O, Kloting N, Sparwasser A, Weickert MO, et al. (2012) Insulin up-
regulates natriuretic peptide clearance receptor expression in the subcutaneous fat depot in obese
subjects: a missing link between CVD risk and obesity? J Clin Endocrinol Metab 97:E731–739.
33. Carlsson AC, Riserus U, Engstrom G, Arnlov J, Melander O, et al. (2013) Novel and established
anthropometric measures and the prediction of incident cardiovascular disease: a cohort study.
Int J Obes 37:1579–85.
34. Bener A, Yousafzai MT, Darwish S, Al-Hamaq AO, Nasralla EA, et al. (2013) Obesity index that better
predict metabolic syndrome: body mass index, waist circumference, waist hip ratio, or waist height ratio.
J Obes 2013:269038.
NT-ProBNP, Obesity and Heart Failure Risk
PLOS ONE | DOI:10.1371/journal.pone.0113710 November 25, 2014 15 / 16
35. Shimabukuro M, Higa N, Asahi T, Yamakawa K, Oshiro Y, et al. (2011) Impaired glucose tolerance,
but not impaired fasting glucose, underlies left ventricular diastolic dysfunction. Diabetes care 34:686–
690.
NT-ProBNP, Obesity and Heart Failure Risk
PLOS ONE | DOI:10.1371/journal.pone.0113710 November 25, 2014 16 / 16
